Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Miroslav Zotovic

Pulmonary Disease Aiken, SC Medical Doctor

NPI 1649388026 CMS profile 346887

68 Physician Dr, Aiken, SC 29801

Open in the dashboard

General payments

$7,285

390 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Miroslav Zotovic of Aiken, SC is reported in the CMS Open Payments database as having received $7,285 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,079 42
2022 General $1,068 61
2021 General $1,175 65
2020 General $1,214 65
2019 General $2,749 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miroslav Zotovic
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Miroslav Zotovic were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Miroslav Zotovic Pulmonary Disease median Middle half National median
2019 $2,749 $377 $109–$1,340 $163
2020 $1,214 $230 $56–$907 $114
2021 $1,175 $269 $68–$1,072 $132
2022 $1,068 $390 $100–$1,457 $149
2023 $1,079 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $1,400 86 payments
  2. AstraZeneca Pharmaceuticals LP $1,250 67 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $833 45 payments
  4. Grifols USA, LLC $461 25 payments
  5. Insmed, Inc. $437 24 payments
  6. Actelion Pharmaceuticals US, Inc. $274 16 payments
  7. Sunovion Pharmaceuticals Inc. $257 16 payments
  8. United Therapeutics Corporation $255 15 payments
  9. Genzyme Corporation $235 11 payments
  10. Regeneron Healthcare Solutions, Inc. $210 9 payments
  11. Other $1,674 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,183 388 payments
  2. Education $102 2 payments
Products named General payments · program years 2019–2023
  1. TRELEGY ELLIPTA $962 57 payments
  2. Prolastin-C Liquid $461 25 payments
  3. OFEV $442 25 payments
  4. Arikayce $437 24 payments
  5. SYMBICORT $398 23 payments
  6. BREZTRI $343 23 payments
  7. FASENRA $305 8 payments
  8. SPIRIVA RESPIMAT $220 13 payments
  9. LONHALA MAGNAIR $215 14 payments
  10. DUPIXENT $210 9 payments
  11. Other $4,589 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

310

Median for Internal Medicine: 777

Drug cost

$149,927

Median for Internal Medicine: $73,373

Branded share of claims

71.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolastin C Alpha-1-Proteinase Inhibitor Brand 11 $74,035
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 67 $59,924
Spiriva Respimat Tiotropium Bromide Brand 12 $6,240
Symbicort Budesonide/Formoterol Fumarate Brand 17 $4,322
Albuterol Sulfate Hfa Albuterol Sulfate Brand 71 $2,548
Theophylline Er Theophylline Anhydrous Brand 44 $2,216
Montelukast Sodium Generic 75 $584
Prednisone Generic 13 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$49,554

Medicare's payments for the services billed

Medicare patients

88

Average age 76

Services billed

394

44 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Heart failure 50%
Arthritis 50%
Chronic kidney disease 45%
Atrial fibrillation 42%
COPD 42%
Depression 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record